LOS ANGELES – CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and research facility. ISO 9001 certification recognizes excellence in quality management standards of an organization that places an emphasis on its customers, the motivation and implication of top management, the process approach and continual improvement.
“As a leading drug delivery technology company with both consumer brands and pharmaceutical products, it is imperative that we ensure our operations are up to the highest standards possible, and this certification only further illustrates our goals,” said Rob Davidson, CEO of CURE. “We understand that our operational processes directly affect users of our products and we are committed to adhering to if not surpassing the standards set by the ISO. We employ a constant improvement mentality across our organization, which aligns with these standards, and will continue to seek out registrations, certifications and approvals by the various regulatory bodies that keep our Company ahead of the competition in terms of quality standards across nutraceutical and pharmaceutical manufacturing.”
ISO certification is granted through a third party and confirms that CURE’s standard operating procedures are up to the strict standards developed and published by the ISO. The certification also demonstrates the Company’s dedication to upholding global standards for quality assurance and quality management.
ISO is an independent, non-governmental international organization that supports innovation and the development of solutions to global issues through its standardized guidelines. Over one million organizations worldwide are independently certified, making ISO 9001 one of the most widely used management tools in the world today.
To learn more about CURE, visit https://curepharmaceutical.com/.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward-Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005264/en/
Licensing Contact:
Jonathan Berlent
Chief Business Officer, CURE Pharmaceutical
Jberlent@curepharma.com
516.660.9148
Investment Contact:
investors@curepharma.com
Gary Zwetchkenbaum, Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662
Media Contacts:
Monica M. Jaramillo, mjaramillo@labeltheagency.com
Kathryn Brown, CMW Media, kathryn@cmwmedia.com
